International Stem Cell Corp 

(Public, OTC:ISCO)   Watch this stock   
Find more results for ISCO
Nov 16, 2009
Q3 2009 INTERNATIONAL STEM CELL CORP Earnings Release
  

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -1086.12% -1306.36%
Operating margin -539.07% -1100.00%
EBITD margin - -1067.59%
Return on average assets -550.48% -342.24%
Return on average equity - -2543.84%
Employees 29 -

Address

2595 Jason Court
Oceanside, CA 92056
United States - Map
+1-760-9406383 (Phone)

Website links

International Stem Cell Corp discussions

  View all discussions »

Description

International Stem Cell Corporation, incorporated is a biotechnology company. The Company is focused on developing therapeutic products and research products. It is in development-stage. The Company’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease, corneal disease, and retinal disease through cell transplant therapy.

Officers and directors

Kenneth C. Aldrich
Chairman of the Board
Age: 70
Andrey Semechkin Ph.D.
Chief Executive Officer, Director
Age: 50
Brian Lundstrom
President
Age: 47
Ray Wood
Principal Financial Officer, Vice President - Finance
Jeffrey D. Janus
Senior Vice President, Chief Executive Officer of Lifeline Cell Technology, Director
Age: 52
Donald A. Wright
Director
Age: 55
Paul V. Maier
Director
Age: 61
Rouslan Semechkin
Director
Age: 24